AU2014331841B2 - Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease - Google Patents

Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease Download PDF

Info

Publication number
AU2014331841B2
AU2014331841B2 AU2014331841A AU2014331841A AU2014331841B2 AU 2014331841 B2 AU2014331841 B2 AU 2014331841B2 AU 2014331841 A AU2014331841 A AU 2014331841A AU 2014331841 A AU2014331841 A AU 2014331841A AU 2014331841 B2 AU2014331841 B2 AU 2014331841B2
Authority
AU
Australia
Prior art keywords
antibodies
ibs
vinculin
level
cdt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014331841A
Other languages
English (en)
Other versions
AU2014331841A1 (en
Inventor
Christopher Chang
Mark Pimentel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52813648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014331841(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of AU2014331841A1 publication Critical patent/AU2014331841A1/en
Application granted granted Critical
Publication of AU2014331841B2 publication Critical patent/AU2014331841B2/en
Priority to AU2020203468A priority Critical patent/AU2020203468A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ecology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2014331841A 2013-10-09 2014-10-09 Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease Active AU2014331841B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020203468A AU2020203468A1 (en) 2013-10-09 2020-05-27 Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361888658P 2013-10-09 2013-10-09
US61/888,658 2013-10-09
PCT/US2014/059957 WO2015054529A1 (en) 2013-10-09 2014-10-09 Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020203468A Division AU2020203468A1 (en) 2013-10-09 2020-05-27 Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease

Publications (2)

Publication Number Publication Date
AU2014331841A1 AU2014331841A1 (en) 2016-03-24
AU2014331841B2 true AU2014331841B2 (en) 2020-03-12

Family

ID=52813648

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014331841A Active AU2014331841B2 (en) 2013-10-09 2014-10-09 Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease
AU2020203468A Abandoned AU2020203468A1 (en) 2013-10-09 2020-05-27 Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020203468A Abandoned AU2020203468A1 (en) 2013-10-09 2020-05-27 Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease

Country Status (19)

Country Link
US (2) US9851361B2 (OSRAM)
EP (1) EP3054977B1 (OSRAM)
JP (1) JP6567509B2 (OSRAM)
KR (1) KR102259588B1 (OSRAM)
CN (1) CN105744956B (OSRAM)
AU (2) AU2014331841B2 (OSRAM)
BR (1) BR112016007474A2 (OSRAM)
CA (1) CA2923651C (OSRAM)
CL (1) CL2016000820A1 (OSRAM)
ES (1) ES2892905T3 (OSRAM)
IL (1) IL244971B2 (OSRAM)
MX (1) MX383423B (OSRAM)
NZ (1) NZ717633A (OSRAM)
PE (1) PE20160882A1 (OSRAM)
PL (1) PL3054977T3 (OSRAM)
PT (1) PT3054977T (OSRAM)
RU (1) RU2683781C2 (OSRAM)
SG (1) SG11201601733VA (OSRAM)
WO (1) WO2015054529A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
WO2014042828A2 (en) 2012-09-17 2014-03-20 Cedars-Sinai Medical Center Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia
MX383424B (es) 2009-02-11 2025-03-14 Cedars Sinai Medical Center Anticuerpo contra toxina de distensión citoletal de campylobacter jejuni
CA2923651C (en) 2013-10-09 2023-03-14 Cedars-Sinai Medical Center Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease
JP6784669B2 (ja) 2014-10-09 2020-11-11 シーダーズ−サイナイ メディカル センター 炎症性腸疾患及びセリアック病から過敏性腸症候群を識別するための方法及びシステム
CN106053827A (zh) * 2016-05-17 2016-10-26 上海凯璟生物科技有限公司 一种肠易激综合症标志物Vinculin抗体检测试剂盒及其制备方法
CN105784989A (zh) * 2016-05-17 2016-07-20 上海凯璟生物科技有限公司 一种肠易激综合症标志物CdtB抗体检测试剂盒及其制备方法
CN109476698B (zh) * 2016-05-20 2023-10-17 西达-赛奈医疗中心 基于基因的炎性肠病诊断
JP2020507755A (ja) 2017-01-30 2020-03-12 シーダーズ−サイナイ メディカル センター 強皮症の診断法
RU2763258C1 (ru) * 2020-07-13 2021-12-28 Евгения Николаевна Воронина Способ дифференциальной диагностики воспалительных заболеваний кишечника у детей по комплексу клинико-анамнестических, лабораторных и инструментальных критериев

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014042828A2 (en) * 2012-09-17 2014-03-20 Cedars-Sinai Medical Center Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691151A (en) * 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
FR2806805A1 (fr) 2000-03-22 2001-09-28 Centre Nat Rech Scient SEQUENCE PEPTIDIQUES COMPRENANT UN OU PLUSIEURS MOTIFS DE LIAISON AUX PROTEINES DE LA FAMILLE Ena/VASP, ET LEURS UTILISATIONS
US20040018528A1 (en) * 2002-05-17 2004-01-29 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
AU2003291625B2 (en) 2002-09-16 2009-10-08 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7595386B2 (en) 2003-01-24 2009-09-29 William Beaumont Hospital Methods and compositions for heat activated gene therapy using cytolethal distending toxin
BRPI0409128A (pt) * 2003-04-08 2006-03-28 Progenics Pharm Inc uso de antagonistas de opióides periféricos, especialmente metilnaltrexona para tratar sìndrome de intestino irritável
WO2005029091A2 (en) * 2003-09-15 2005-03-31 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases
US7563594B2 (en) 2003-12-05 2009-07-21 Fuso Pharmaceutical Industries, Ltd. Cytolethal distending toxins and detection of Campylobacter bacteria using the same as a target
WO2008140484A2 (en) 2006-11-09 2008-11-20 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
CA2747253A1 (en) 2007-12-20 2009-07-02 Index Diagnostics Ab Method and kit for use in the differentiation of ibd and ibs and further distinction between disease types of ibd
ES2529060T3 (es) 2008-11-24 2015-02-16 Cedars-Sinai Medical Center Derivados antioxidantes de la camptotecina y nanoesferas antineoplásicas antioxidantes de los mismos
MX383424B (es) 2009-02-11 2025-03-14 Cedars Sinai Medical Center Anticuerpo contra toxina de distensión citoletal de campylobacter jejuni
US20110294726A1 (en) 2009-02-11 2011-12-01 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
FR2942541A1 (fr) 2009-02-25 2010-08-27 Assist Publ Hopitaux De Paris Procede de diagnostic d'une vascularite
RU2397178C1 (ru) * 2009-02-27 2010-08-20 Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Диагностическая тест-система в формате иммуночипа и способ серологической дифференциальной диагностики сифилиса
IT1400989B1 (it) 2010-07-13 2013-07-05 Segix Italia S R L Ora Istituto Biochimico Naz Savio S R L Forme di somministrazione orale a rilascio controllato di rifampicina per il trattamento di infezioni batteriche dell' apparato intestinale.
GB201017520D0 (en) 2010-10-15 2010-12-01 Sense Proteomic Ltd Biomarkers
CA2923651C (en) 2013-10-09 2023-03-14 Cedars-Sinai Medical Center Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease
JP6784669B2 (ja) 2014-10-09 2020-11-11 シーダーズ−サイナイ メディカル センター 炎症性腸疾患及びセリアック病から過敏性腸症候群を識別するための方法及びシステム
CN106091069A (zh) 2016-06-15 2016-11-09 安徽省绿巨人环境技术有限公司 一种废水再利用装置
JP2020507755A (ja) 2017-01-30 2020-03-12 シーダーズ−サイナイ メディカル センター 強皮症の診断法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014042828A2 (en) * 2012-09-17 2014-03-20 Cedars-Sinai Medical Center Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MORALES W. ET AL., "Antibodies to cytolethal distending toxin B and auto-antibodies to human vinculin are elevated in IBS subjects", GASTROENTEROL., (2013), vol. 144, no. 5, page S-914 *

Also Published As

Publication number Publication date
SG11201601733VA (en) 2016-04-28
CN105744956A (zh) 2016-07-06
AU2020203468A1 (en) 2020-06-18
HK1221898A1 (zh) 2017-06-16
MX2016004167A (es) 2016-06-24
WO2015054529A1 (en) 2015-04-16
US20170038393A1 (en) 2017-02-09
US20180196063A1 (en) 2018-07-12
PE20160882A1 (es) 2016-09-14
JP6567509B2 (ja) 2019-08-28
BR112016007474A2 (pt) 2017-09-12
CA2923651C (en) 2023-03-14
IL244971B2 (en) 2023-12-01
EP3054977A1 (en) 2016-08-17
NZ717633A (en) 2021-07-30
IL244971A0 (en) 2016-05-31
RU2683781C2 (ru) 2019-04-02
KR20160062161A (ko) 2016-06-01
ES2892905T3 (es) 2022-02-07
MX383423B (es) 2025-03-14
CN105744956B (zh) 2021-07-20
JP2017502253A (ja) 2017-01-19
CL2016000820A1 (es) 2016-09-23
EP3054977B1 (en) 2021-07-21
PT3054977T (pt) 2021-10-14
RU2016116766A (ru) 2017-11-15
CA2923651A1 (en) 2015-04-16
PL3054977T3 (pl) 2021-12-20
AU2014331841A1 (en) 2016-03-24
IL244971B1 (en) 2023-08-01
US10352944B2 (en) 2019-07-16
US9851361B2 (en) 2017-12-26
KR102259588B1 (ko) 2021-06-02
EP3054977A4 (en) 2017-04-12

Similar Documents

Publication Publication Date Title
AU2014331841B2 (en) Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease
US10690679B2 (en) Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
US10466254B2 (en) Method of measuring a level of anti-vinculin antibodies in a biological sample
US20240159772A1 (en) Methods for Detecting and Treating Irritable Bowel Syndrome
HK1221898B (en) Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease
HK1234824A1 (en) Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
HK1234824B (en) Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)